Zydus Lifesciences' Sentynl and BridgeBio Partner to Advance Rare Disease Treatment

Services

Stock Market Masterclass

Equity Trading with CA Abhay

FNO Stocks with CA Abhay

Equity Investment with CA Abhay

Option Trading with CA Abhay

Zydus Lifesciences' Sentynl and BridgeBio Partner to Advance Rare Disease Treatment

Team FS

06/May/2024

Key Points:

Life-Saving Collaboration: Sentynl Therapeutics and BridgeBio Pharma join forces to enhance treatment for rare genetic disorder, MoCD Type A.
Global Impact: Zydus Lifesciences' acquisition of NULIBRY™ aims to address unmet healthcare needs for children with rare diseases worldwide.
Commitment to Patients: The partnership underscores a shared commitment to empowering patients and improving lives through innovative therapies.

In a significant development in the field of rare disease treatment, Sentynl Therapeutics, a subsidiary of Zydus Lifesciences Ltd., and BridgeBio Pharma have announced a strategic collaboration to advance the treatment for molybdenum cofactor deficiency (MoCD) Type A. This partnership marks a crucial step towards addressing the urgent healthcare needs of children battling this ultra-rare, life-threatening genetic disorder.

Life-Saving Collaboration: Sentynl and BridgeBio Join Forces
Sentynl Therapeutics, a U.S.-based biopharmaceutical company, and BridgeBio Pharma, a leader in genetic diseases and cancers, have come together to execute an asset purchase agreement for the sale of BridgeBio's NULIBRY™ (Fosdenopterin) for Injection. NULIBRY™, approved by the U.S. Food and Drug Administration (USFDA), is designed to reduce the risk of mortality in patients with MoCD Type A. This strategic collaboration underscores the shared commitment of both companies to deliver innovative therapies that can make a life-saving difference for patients facing rare diseases.

Global Impact: Addressing Unmet Healthcare Needs
With the acquisition of NULIBRY™, Zydus Lifesciences Ltd. aims to bridge the unmet healthcare needs of children suffering from rare and orphan pediatric diseases, including MoCD Type A. The company's subsidiary, Sentynl, is dedicated to facilitating early diagnosis and treatment through enhanced awareness, newborn screening, genetic testing, and patient support initiatives. Additionally, Zydus Lifesciences Ltd. is actively involved in the development of treatments for rare diseases, such as Menkes Disease, in collaboration with Cyprium Therapeutics, Inc.

Commitment to Patients: Empowering Lives through Innovation
Dr. Sharvil Patel, Managing Director of Zydus Lifesciences Ltd., emphasized the company's core purpose of empowering patients suffering from rare diseases to live healthier and fulfilled lives. The agreement with BridgeBio represents a significant step towards fulfilling this purpose, particularly for children affected by MoCD Type A. By leveraging Sentynl's expertise in the rare pediatric neurodevelopment space and its strong relationships with healthcare providers, the collaboration aims to ensure that innovative treatments like NULIBRY™ reach patients who need them most.

In conclusion, the partnership between Sentynl Therapeutics, BridgeBio Pharma, and Zydus Lifesciences Ltd. signifies a collective commitment to advancing rare disease treatment and improving patient outcomes. As efforts intensify to address unmet healthcare needs and provide hope for patients with rare genetic disorders, collaborations like these play a vital role in driving innovation and making life-saving therapies accessible to those who need them most.

Also Read : Aurobindo Pharma's facility in Rajasthan concludes US FDA audit with nine observations

Join our Telegram Channel and WhatsApp Channel for regular Updates.

Services

Zydus Lifesciences' Sentynl and BridgeBio Partner to Advance Rare Disease Treatment

Related News